Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.
Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.
复制标题
DOI：
10.1161/circulationaha.113.005119
复制
发表时间：
2014-02-25
期刊：
影响因子：
37.8
通讯作者：
Murray CJ
中科院分区：
文献类型：
--
作者：
Chugh SS;Havmoeller R;Narayanan K;Singh D;Rienstra M;Benjamin EJ;Gillum RF;Kim YH;McAnulty JH Jr;Zheng ZJ;Forouzanfar MH;Naghavi M;Mensah GA;Ezzati M;Murray CJ
心房颤动（AF）的全球负担尚不清楚。我们系统地回顾了1980-2010年发表的基于人群的房颤研究，这些研究来自21个全球疾病负担（GBD）地区，以估计与房颤相关的全球/区域患病率、发病率以及发病率和死亡率（DisModMR软件）。在确定的377项潜在研究中，184项符合预先规定的资格标准。2010年全球估计房颤患者人数为3350万[其中男性为2090万（UI， 1950 - 2220万），女性为1260万（UI， 120 - 1370万）]。以残疾调整生命年（DALYs）衡量的与房事相关的负担，从1990年到2010年，男性增加了18.8% (UI, 15.8 - 19.3)，女性增加了18.9% （UI, 15.8 - 23.5）。1990年，男性经年龄调整后的房颤患病率（每10万人）为569.5[95%不确定区间（UI）， 532·8 ~ 612·7]，女性为359·9 (UI, 334·7 ~ 392·6)；经年龄调整后的发病率男性为60·7/10万人年（UI, 49.2 - 78.5），女性为43·8 （UI, 35.9 - 55.0）。2010年男性患病率为596·2 (UI, 558·4 ~ 636·7)，女性患病率为373·1 (UI, 347·9 ~ 402·2)；男性发病率为77.5 (UI, 65·2 ~ 95.4)，女性为59.5 （UI, 49·9 ~ 74·9）。与房颤相关的死亡率在女性中较高，1990 - 2010年男性和女性分别增加了2倍（UI, 2.0 - 2.0）和1.9倍（UI, 1.8 - 2.0）。这些发现提供了1990-2010年间总体负担、发病率、流行率和af相关死亡率逐步增加的证据。需要对房颤进行系统的全球监测，以更好地指导预防和治疗战略。
The global burden of atrial fibrillation (AF) is unknown. We systematically reviewed population-based studies of AF published 1980–2010, from the 21 Global Burden of Disease (GBD) regions to estimate global/regional prevalence, incidence, as well as morbidity and mortality related to AF (DisModMR software). Of 377 potential studies identified, 184 met pre-specified eligibility criteria. The estimated number of individuals with AF globally in 2010 was 33·5 million [(20·9 million males (UI, 19·5–22·2 million) and 12·6 million females (UI, 12·0–13·7 million)]. Burden associated with AF, measured as disability adjusted life-years (DALYs), increased by 18·8% (UI, 15·8–19·3) in males and 18·9% (UI, 15·8–23·5) in females, from 1990 to 2010. In 1990, the estimated age-adjusted prevalence rates of AF (per 100,000 population) were 569·5 in males [95% uncertainty interval (UI), 532·8–612·7] and 359·9 in females (UI, 334·7–392·6); the estimated age-adjusted incidence rates were 60·7/100,000 person-years in males (UI, 49·2–78·5) and 43·8 in females (UI, 35·9–55·0). In 2010 the prevalence rate increased to 596·2 (UI, 558·4–636·7) in males and 373·1 (UI, 347·9–402·2) in females; incidence rate increased to 77·5 (UI, 65·2–95·4) in males and 59·5 (UI, 49·9–74·9) in females. Mortality associated with AF was higher in females, and increased by 2-fold (UI, 2·0–2·2) and 1·9-fold (UI, 1·8–2·0) in males and females, respectively, from 1990 to 2010. These findings provide evidence of progressive increases in overall burden, incidence, prevalence and AF-associated mortality between 1990–2010. Systematic, global surveillance of AF is required to better direct prevention and treatment strategies.